A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Completed · Phase 1

Conditions studied: Healthy, Hepatic Insufficiency

In brief

The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.

Key facts

Study ID: NCT05916560
Run by: Eli Lilly and Company
People needed: 43
Starts: 2023-07-13
Expected to finish: 2025-03-02
Last updated by the study team: 2025-04-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

All Participants:
Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
Healthy or various degrees of hepatic impairment depending on the study group

You may not qualify if…

Participants with hepatic impairment:
Have or are anticipating an organ transplant within the next 6 months
Requires needle evacuation of ascites fluid more than 2 times per month
Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure

Where it is running

Arizona Clinical Trials - Chandler — Chandler, Arizona, United States
Accel Research Sites- Clinical Research Unit — DeLand, Florida, United States
Advanced Pharma Clinical Research — Miami, Florida, United States
American Research Corporation at Texas Liver Institute — San Antonio, Texas, United States
Pinnacle Clinical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.